Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival

Authors: Juan C Scornik, Jonathan S Bromberg, Douglas J Norman, Mayank Bhanderi, Matthew Gitlin, Jeffrey Petersen

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Blood transfusions have the potential to improve graft survival, induce sensitization, and transmit infections. Current clinical practice is to minimize transfusions in renal transplantation candidates, but it is unclear if the evidence continues to support pre-transplant transfusion avoidance. Changes in the Medicare prospective payment system may increase transfusion rates. Thus there is a need to re-evaluate the literature to improve the management options for renal transplant candidates.

Methods

A review applying a systematic approach and conducted using MEDLINE®, Embase®, and the Cochrane Library for English-language publications (timeframe: 01/1984–03/2011) captured 180 studies and data from publically available registries and assessed the impact of transfusions on allosensitization and graft survival, and the impact of allosensitization on graft survival and wait time.

Results

Blood transfusions continued to be a major cause of allosensitization, with allosensitization associated with increased rejection and graft loss, and longer wait times to transplantation. Although older studies showed a beneficial effect of transfusion on graft survival, this benefit has largely disappeared in the post-cyclosporine era due to improved graft outcomes with current practice. Recent data suggested that it may be the donor-specific antibody component of allosensitization that carried the risk to graft outcomes.

Conclusions

Results of this review indicated that avoiding transfusions whenever possible is a sound management option that could prevent detrimental effects in patients awaiting kidney transplantation.
Appendix
Available only for authorised users
Literature
1.
Pfaff WW, Howard RJ, Scornik JC, Day C, Renderer J, Scott J, Fennel RS, Peterson JC, Salomon DR, Patton PR: Incidental and purposeful random donor blood transfusion. Sensitization and transplantation. Transplantation. 1989, 47 (1): 130-133. 10.1097/00007890-198901000-00029.CrossRefPubMed
2.
Sautner T, Gnant M, Banhegyi C, Wamser P, Gotzinger P, Steininger R, Muhlbacher F: Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. Transpl Int. 1992, 5 (SUPPL. 1): S116-S120.PubMed
3.
Macdougall IC: Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol. 2008, 3 (1): 200-207. 10.2215/CJN.03840907.CrossRefPubMed
4.
5.
6.
USRDS: US Renal Data System, USRDS. 2012, Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Available at http://​www.​usrds.​org/​atlas12.​aspx. Access date: April 2013, Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States
7.
8.
9.
10.
Downs SH, Black N: The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998, 52 (6): 377-384. 10.1136/jech.52.6.377.CrossRefPubMedPubMedCentral
11.
Kennelly J: Methodological approach to assessing the evidence. Reducing racial/ethnic disparities in reproductive and perinatal outcomes: the evidence from population-based interventions. Edited by: Handler A, Kennelly J, Peacock N. 2011, New York, NY: Springer, 7-19.CrossRef
12.
Cinti P, Pretagostini R, Arpino A, Tamburro ML, Mengasini S, Lattanzi R, De Simone P, Berloco P, Molajoni ER: Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation. 2005, 79 (5): 599-601.PubMed
13.
Cinti P, Pretagostini R, Lai Q, Tamburro ML, Rossi M, Poli L, Berloco P: Alloantibodies and outcomes of deceased donor kidney allografts. Hum Immunol. 2009, 70 (8): 651-654. 10.1016/j.humimm.2009.06.008.CrossRefPubMed
14.
Domingues EM, Matuck T, Graciano ML, Souza E, Rioja S, Falci MC, Monteiro De Carvalho DB, Porto LC: Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant. Clin Transplant. 2010, 24 (6): 821-829. 10.1111/j.1399-0012.2009.01182.x.CrossRefPubMed
15.
Ishida H, Tanabe K, Furusawa M, Ishizuka T, Hayashi T, Tokumoto T, Miyamoto N, Shirakawa H, Shimimura H, Shimizu T, et al: Evaluation of flow cytometric panel reactive antibody in renal transplant recipients - examination of 238 cases of renal transplantation. Transpl Int. 2005, 18 (2): 163-168. 10.1111/j.1432-2277.2004.00048.x.CrossRefPubMed
16.
Kimball PM, Baker MA, Wagner MB, King A: Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection. Kidney Int. 2011, 79 (10): 1131-1137. 10.1038/ki.2010.556.CrossRefPubMedPubMedCentral
17.
Direskeneli H, Ozgun S, Ozener C, Lawrence R, Erman M, Sarsmaz N, Akoglu E: Anti-lymphocyte, anti-monocyte, and anti-endothelial cell antibodies in chronic haemodialysis patients. Nephrol Dial Transplant. 1992, 7 (5): 422-426.PubMed
18.
Hahn AB, Kasten-Jolly JC, Constantino DM, Graffunder E, Conti DJ: Promoter-region alleles of the TNF-(alpha) and IL-10 genes have no effect on pretransplant alloantibody production. Transplantation. 2001, 72 (4): 739-742. 10.1097/00007890-200108270-00032.CrossRefPubMed
19.
Koyle MA, Rajfer J, Mickey MR, Glassock RJ, Ward HJ: The current role of pre-transplant blood transfusions and tissue typing in cadaveric renal transplantation. J Urol. 1987, 138 (5): 1141-1143.PubMed
20.
Lietz K, Lao M, Paczek L, Gorski A, Gaciong Z: The impact of pretransplant erythropoietin therapy on late outcomes of renal transplantation. Ann Transplant. 2003, 8 (2): 17-24.PubMed
21.
Zou Y, Stastny P, Susal C, Dohler B, Opelz G: Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med. 2007, 357 (13): 1293-1300. 10.1056/NEJMoa067160.CrossRefPubMed
22.
Chequer Bou-Habib J, Krams S, Colombe BW, Lou C, Bubar O, Amend WJC, Salvatierra O, Garovoy MR: Flow cytometric crossmatching and long-term kidney allograft survical in donor-specific transfusion patients. Transplantation. 1991, 51 (2): 543-545. 10.1097/00007890-199102000-00052.CrossRef
23.
Lim EC, Terasaki PI: High survival rate of kidney transplants in IgA nephropathy patients. Clin Transplant. 1992, 6 (2): 100-105.
24.
Soosay A, O’Neill D, Counihan A, Hickey D, Keogan M: Causes of sensitisation in patients awaiting renal transplantation in Ireland. Ir Med J. 2003, 96 (4): 109-112.PubMed
25.
Vanrenterghem Y, Waer M, Roels L, Coosemans W, Christaens MR, Opelz G: A prospective, randomized trial of pretransplant blood transfusions in cadaver kidney transplant candidates. Leuven Collaborative Group for Transplantation. Transpl Int. 1994, 7 (SUPPL.1): S243-S246.CrossRefPubMed
26.
Vathsala A, Chan SH, Wee C, Lim CH: Immunology of renal transplantation in Singapore. Ann Acad Med Singapore. 1988, 17 (2): 218-225.PubMed
27.
USRDS: US Renal Data System, USRDS. 2010, Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Available at http://​www.​usrds.​org/​atlas10.​aspx. Access date: Jan 2012, Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States
28.
Cicciarelli J, Terasaki PI, Mickey MR: The effect of zero HLA class I and II mismatching in cyclosporine-treated kidney transplant patients. Transplantation. 1987, 43 (5): 636-640. 10.1097/00007890-198705000-00006.CrossRefPubMed
29.
Iwaki Y, Cecka JM, Terasaki PI: The transfusion effect in cadaver kidney transplants - yes or no. Transplantation. 1990, 49 (1): 56-59. 10.1097/00007890-199001000-00012.CrossRefPubMed
30.
Opelz G, Vanrenterghem Y, Kirste G, Gray DWR, Horsburgh T, Lachance JG, Largiader F, Lange H, Vujaklija-Stipanovic K, varez-Grande J, et al: Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation. 1997, 63 (7): 964-967. 10.1097/00007890-199704150-00010.CrossRefPubMed
31.
Takiff H, Cook DJ, Himaya NS, Mickey MR, Terasaki PI: Dominant effect of histocompatibility on ten-year kidney transplant survival. Transplantation. 1988, 45 (2): 410-415. 10.1097/00007890-198802000-00033.CrossRefPubMed
32.
Eigidi M, Scott DH, Corry RJ: The effect of transfusions on renal allograft survival in the cyclosporine era: a single center report. Clin Transplant. 1993, 7 (3): 240-244.
33.
Melzer JS, Husing RM, Feduska NJ: The beneficial effect of pretreatment blood transfusions in cyclosporine-treated cadaver renal allograft recipients. Transplantation. 1987, 43 (1): 61-64. 10.1097/00007890-198701000-00014.CrossRefPubMed
34.
Sanfilippo F, Thacker L, Vaughn WK: Living-donor renal transplantation in SEOPF. The impact of histocompatibility, transfusions, and cyclosporine on outcome. Transplantation. 1990, 49 (1): 25-29. 10.1097/00007890-199001000-00006.CrossRefPubMed
35.
Benfield MR, McDonald R, Sullivan EK, Stablein DM, Tejani A: The 1997 annual renal transplantation in children report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant. 1999, 3 (2): 152-167. 10.1034/j.1399-3046.1999.00011.x.CrossRefPubMed
36.
Hiesse C, Busson M, Buisson C, Farahmand H, Bierling P, Benbunan M, Bedrossian J, Aubert P, Glotz D, Loirat C, et al: Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. Kidney Int. 2001, 60 (1): 341-349. 10.1046/j.1523-1755.2001.00805.x.CrossRefPubMed
37.
Kerman RH, Kimball PM, Van Buren CT, Lewis RM, Kahan BD: Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation. 1991, 51 (2): 338-342. 10.1097/00007890-199102000-00013.CrossRefPubMed
38.
Poli F, Mascaretti L, Pappalettera M, Scalamonga M, Bernardi L, Sirchia G: HLA-DRB1 compatibility in cadaver kidney transplantation: correlation with graft survival and function. Transpl Int. 1995, 8 (2): 91-95. 10.1111/j.1432-2277.1995.tb01482.x.CrossRefPubMed
39.
Hanish SI, Samaniego M, Mezrich JD, Foley DP, Leverson GE, Lorentzen DF, Sollinger HW, Pirsch JD, Alessandro AM, Fernandez LA: Outcomes of simultaneous liver/kidney transplants are equivalent to kidney transplant alone: a preliminary report. Transplantation. 2010, 90 (1): 52-60. 10.1097/TP.0b013e3181e17014.CrossRefPubMedPubMedCentral
40.
Karpinski M, Rush D, Jeffery J, Exner M, Regele H, Dancea S, Pochinco D, Birk P, Nickerson P: Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol. 2001, 12 (12): 2807-2814.PubMed
41.
Mai ML, Ahsan N, Wadei HM, Genco PV, Geiger XJ, Willingham DL, Taner CB, Hewitt WR, Grewal HP, Nguyen JHH, et al: Excellent renal allograft survival in donor-specific antibody positive transplant patients - role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation. 2009, 87 (2): 227-232. 10.1097/TP.0b013e31818c962b.CrossRefPubMed
42.
Riethmuller S, Ferrari-Lacraz S, Muller MK, Raptis DA, Hadaya K, Rusi B, Laube G, Schneiter G, Fehr T, Villard J: Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation. 2010, 90 (2): 160-167. 10.1097/TP.0b013e3181e36e08.CrossRefPubMed
43.
Scornik JC, Clapp W, Patton PR, Van Der Werf WJ, Hemming AW, Reed AI, Howard RJ: Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation. 2001, 71 (8): 1098-1102. 10.1097/00007890-200104270-00015.CrossRefPubMed
44.
Vlad G, Ho EK, Vasilescu ER, Colovai AI, Stokes MB, Markowitz GS, Agati VD, Cohen DJ, Ratner LE, Suciu-Foca N: Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol. 2009, 70 (8): 589-594. 10.1016/j.humimm.2009.04.018.CrossRefPubMed
45.
Zhang Q, Liang LW, Gjertson DW, Lassman C, Wilkinson AH, Kendrick E, Pham PTT, Danovitch GM, Gritsch HA, Reed EF: Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation. 2005, 79 (5): 591-598. 10.1097/01.TP.0000155246.52249.AC.CrossRefPubMed
46.
Bielmann D, Honger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S: Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant. 2007, 7 (3): 626-632. 10.1111/j.1600-6143.2007.01667.x.CrossRefPubMed
47.
Eng HS, Bennett G, Tsiopelas E, Lake M, Humphreys I, Chang SH, Coates PTH, Russ GR: Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant. 2008, 8 (11): 2335-2342. 10.1111/j.1600-6143.2008.02387.x.CrossRefPubMed
48.
Mahmoud KM, Ismail AM, Sheashaa HA, Gheith OA, Kamal MM, Ghoneim MA: Value of donor-specific antibody detection in first-graft renal transplant recipients with a negative complement-dependent cytotoxic crossmatch. Exp Clin Transplant. 2009, 7 (2): 124-128.PubMed
49.
Vaidya S, Partlow D, Barnes T, Gugliuzza K: Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies. Transplantation. 2006, 82 (12): 1606-1609. 10.1097/01.tp.0000248530.66421.50.CrossRefPubMed
50.
Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC: Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?. Transplantation. 2008, 85 (8): 1200-1204. 10.1097/TP.0b013e31816b1c37.CrossRefPubMed
51.
Le Bas-Bernardet S, Hourmant M, Valentin N, Paitier C, Giral-Classe M, Curry S, Follea G, Soulillou JP, Bignon JD: Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation. 2003, 75 (4): 477-482. 10.1097/01.TP.0000047311.77702.59.CrossRefPubMed
52.
Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD: Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol. 2009, 70 (8): 584-588. 10.1016/j.humimm.2009.05.007.CrossRefPubMed
53.
Poggio ED, Augustine JJ, Clemente M, Danzig JM, Volokh N, Zand MS, Hricik DE, Heeger PS: Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation. 2007, 83 (7): 847-852. 10.1097/01.tp.0000258730.75137.39.CrossRefPubMed
54.
Pratico-Barbato L, Conca R, Magistroni P, Leonardi G, Oda A, Rosati F, Leone E, Tacconella M, Roggero S, Segoloni GP, et al: B cell positive cross-match not due to anti-HLA class I antibodies and first kidney graft outcome. Transpl Immunol. 2008, 19 (3–4): 238-243.CrossRefPubMed
55.
Wang D, Wu WZ, Yang SL, Chen JH, Tan JM: Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients. Chin Med J (Engl). 2006, 119 (20): 1683-1688.
56.
Kimball P, Wagner B, King A, Fisher RA, Dawson S, Cotterell A, Posner M: Comparison of two drug regimens upon clinical outcome among renal transplant recipients with positive flow cytometric crossmatches. Clin Transplant. 2002, 16 (4): 290-294. 10.1034/j.1399-0012.2002.01147.x.CrossRefPubMed
57.
Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C: Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010, 21 (8): 1398-1407. 10.1681/ASN.2009101065.CrossRefPubMedPubMedCentral
58.
Meng HL, Jin XB, Li XT, Wang HW, Lu JJ: Impact of human leukocyte antigen matching and recipients’ panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Chin Med J (Engl). 2009, 122 (4): 420-426.
59.
Noreen HJ, McKinley DM, Gillingham KJ, Matas AJ, Segall M: Positive remote crossmatch: impact on short-term and long-term outcome in cadaver renal transplantation. Transplantation. 2003, 75 (4): 501-505. 10.1097/01.TP.0000048225.98745.64.CrossRefPubMed
60.
Opelz G: Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet. 2005, 365 (9470): 1570-1576. 10.1016/S0140-6736(05)66458-6.CrossRefPubMed
61.
Rebibou JM, Carvalho Bittencourt M, Saint-Hillier Y, Chabod J, Dupont I, Bittard H, Chalopin JM, Herve P, Tiberghien P: T-cell flow-cytometry crossmatch and long-term renal graft survival. Clin Transplant. 2004, 18 (5): 558-563. 10.1111/j.1399-0012.2004.00226.x.CrossRefPubMed
62.
Bryan CF, Wakefield M, Reese JC, Shield CF, Warady BA, Winklhofer FT, Murillo D: Renal graft survival is not influenced by a positive flow B-cell crossmatch. Clin Transplant. 2007, 21 (1): 72-79. 10.1111/j.1399-0012.2006.00585.x.CrossRefPubMed
63.
Mahoney RJ, Taranto S, Edwards E: B-cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol. 2002, 63 (4): 324-335. 10.1016/S0198-8859(02)00363-4.CrossRefPubMed
64.
Petero VG, Kaposztas Z, Kahan BD: Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplants. Clin Transplant. 2010, 24 (2): 243-251. 10.1111/j.1399-0012.2009.01055.x.CrossRefPubMed
65.
Thompson JS, Thacker Ii LR, Krishnan G: Human leukocyte antigens DR and AB and kidney retransplantation. Transplantation. 2003, 75 (5): 718-723. 10.1097/01.TP.0000048376.79803.C1.CrossRefPubMed
66.
Aubert V, Venetz JP, Pantaleo G, Pascual M: Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol. 2009, 70 (8): 580-583. 10.1016/j.humimm.2009.04.011.CrossRefPubMed
67.
Gibney EM, Cagle LR, Freed B, Warnell SE, Chan L, Wiseman AC: Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant. 2006, 21 (9): 2625-2629. 10.1093/ndt/gfl202.CrossRefPubMed
68.
Roberti I, Vyas S, Pancoska C: Donor-specific antibodies by flow single antigen beads in pediatric living donor kidney transplants: single center experience. Pediatr Transplant. 2007, 11 (8): 901-905. 10.1111/j.1399-3046.2007.00793.x.CrossRefPubMed
69.
Van Den Berg-Loonen EM, Billen EVA, Voorter CEM, Van Heurn LWE, Claas FHJ, Van Hooff JP, Christiaans MHL: Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation. 2008, 85 (8): 1086-1090. 10.1097/TP.0b013e31816b3ed1.CrossRefPubMed
70.
Verghese PS, Smith JM, McDonald RA, Schwartz SM, Nelson KA, Warner PR: Impaired graft survival in pediatric renal transplant recipients with donor-specific antibodies detected by solid-phase assays. Pediatr Transplant. 2010, 14 (6): 730-734. 10.1111/j.1399-3046.2009.01281.x.CrossRefPubMed
71.
Willicombe M, Brookes P, Santos-Nunez E, Galliford J, Ballow A, McLean A, Roufosse C, Cook HT, Dorling A, Warrens AN, et al: Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. Am J Transplant. 2011, 11 (3): 470-477. 10.1111/j.1600-6143.2010.03421.x.CrossRefPubMed
72.
Poli F, Cardillo M, Scalamogna M: Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: the North Italy Transplant program approach. Hum Immunol. 2009, 70 (8): 631-635. 10.1016/j.humimm.2009.06.006.CrossRefPubMed
73.
74.
75.
Bray RA, Nolen JDL, Larsen C, Pearson T, Newell KA, Kokko K, Guasch A, Tso P, Mendel JB, Gebel HM: Transplanting the highly sensitized patient: the emory algorithm. Am J Transplant. 2006, 6 (10): 2307-2315. 10.1111/j.1600-6143.2006.01521.x.CrossRefPubMed
76.
USRDS: US Renal Data System, USRDS. 2011, Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Available at http://​www.​usrds.​org/​atlas11.​aspx. Access date: Feb 2012, Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States
77.
Patel R, Terasaki PI: Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969, 280 (14): 735-739. 10.1056/NEJM196904032801401.CrossRefPubMed
78.
Scornik JC, Meier-Kriesche HU: Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention. Am J Transplant. 2011, 11 (9): 1785-1791. 10.1111/j.1600-6143.2011.03705.x.CrossRefPubMed
79.
Opelz G, Terasaki PI: Dominant effect of transfusions on kidney graft survival. Transplantation. 1980, 29 (2): 153-158. 10.1097/00007890-198002000-00013.CrossRefPubMed
80.
Marti HP, Henschkowski J, Laux G, Vogt B, Seiler C, Opelz G, Frey FJ: Effect of donor-specific transfusions on the outcome of renal allografts in the cyclosporine era. Transpl Int. 2006, 19 (1): 19-26. 10.1111/j.1432-2277.2005.00233.x.CrossRefPubMed
81.
Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen JP, Suberbielle C, Anglicheau D, Verine J, Beuscart T, Nochy D, Bruneval P, et al: Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet. 2013, 381 (9863): 313-319. 10.1016/S0140-6736(12)61265-3.CrossRefPubMed
82.
Macdougall IC, Obrador GT: How important is transfusion avoidance in 2013?. Nephrol Dial Transplant. 2013, 28 (5): 1092-1099. 10.1093/ndt/gfs575.CrossRefPubMed
83.
Obrador GT, Macdougall IC: Effect of red cell transfusions on future kidney transplantation. Clin J Am Soc Nephrol. 2013, 8 (5): 852-860. 10.2215/CJN.00020112.CrossRefPubMed
Metadata
Title
An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival
Authors
Juan C Scornik
Jonathan S Bromberg
Douglas J Norman
Mayank Bhanderi
Matthew Gitlin
Jeffrey Petersen
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-217

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue

Research article

Chronic kidney disease of uncertain aetiology: prevalence and causative factors in a developing country

Research article

Dynamic cardiac dyssynchrony is strongly associated with 2-year dialysis adequacy in continuous ambulatory peritoneal dialysis patients

Case report

Dialysis disequilibrium syndrome induced by neoplastic meningitis in a patient receiving maintenance hemodialysis

Case report

Branchio-Oto-Renal Syndrome (BOR) associated with focal glomerulosclerosis in a patient with a novel EYA1 splice site mutation

Research article

Validation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcome

Research article

Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits